China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered ZoHealth. This collaboration focuses on the development of human gut microbiota, precision nutrition, and health product innovation.
Core Program Focused on Probiotic Products
The core program of the partnership will center around Xbiome’s proprietary bacterial strains, which will be utilized to develop a series of probiotic products aimed at regulating intestinal health and managing weight. This initiative is driven by market demand in both Australia and the United States, highlighting the growing interest in microbiome-based health solutions.
Technical Cooperation in Gut Microbiota Sequencing
Following the development of probiotic products, the collaboration will extend to gut microbiota sequencing technical cooperation, leveraging Xbiome’s AI microbiome research and product development platform. This technical partnership aims to enhance the understanding of gut microbiota and its implications for health, paving the way for innovative dietary and therapeutic interventions.-Fineline Info & Tech
